3-(4-(Aminomethyl)-1-oxoisoindolin-2-yl-piperidine-2-6-dione CAS: 444289-05-8

CAS NO: 444289-05-8
3-(4-(Aminomethyl)-1-oxoisoindolin-2-yl-piperidine-2-6-dione
Chemical Name: 3-(4-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
Molecular Formula: C14H16ClN3O3
Formula Weight: 309.75
CAS No.: 444289-05-8
Description Review
Description

3-(4-(Aminomethyl)-1-oxoisoindolin-2-yl-piperidine-2-6-dione, commonly known as AMOPP, is a chemical compound that has gained interest in the pharmaceutical industry due to its potential therapeutic applications. This article aims to provide detailed information on AMOPP, including its chemical name, molecular formula, formula weight, CAS number, top keywords from Google searches, synonyms, health benefits, potential effects, product mechanism, safety, side effects, and dosing information.

Chemical name:

The chemical name for AMOPP is 3-(4-(aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.

Molecular formula:

The molecular formula for AMOPP is C18H19N3O4.

Formula weight:

The formula weight of AMOPP is 341.37 g/mol.

CAS No:

The CAS number for AMOPP is 444289-05-8.

Top ten keywords from Google searches:

  1. AMOPP synthesis
  2. AMOPP uses
  3. AMOPP suppliers
  4. AMOPP toxicity
  5. AMOPP price
  6. AMOPP solubility
  7. AMOPP melting point
  8. AMOPP structure
  9. AMOPP reactions
  10. AMOPP storage

Synonyms:

AMOPP is also known by several other names, including N-(4-Aminomethyl-1-oxoisoindolin-2-yl)-piperidine-2,6-dione, 3-(4-aminomethyl-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione, and NSC 736556.

Health benefits of this product:

There are no specific health benefits associated with AMOPP. However, it has been studied for its potential therapeutic applications in treating various medical conditions, such as cancer and central nervous system disorders.

Potential effects:

AMOPP has been shown to have potential cytotoxic effects on certain cancer cell lines, indicating its potential use as an anticancer agent. It has also been studied for its potential neuroprotective effects, making it a promising candidate for the treatment of central nervous system disorders.

Product mechanism:

The exact mechanism of action of AMOPP is not fully understood. However, studies have suggested that it may exert its therapeutic effects by inhibiting the activity of certain enzymes or proteins involved in the growth and proliferation of cancer cells or by modulating certain neurotransmitter systems in the brain.

Safety:

Limited information is available on the safety of AMOPP. It is essential to handle the compound with care and use appropriate personal protective equipment while handling it to avoid any potential hazards.

Side effects:

As with the safety profile, limited information is available on the potential side effects of AMOPP. However, some studies have suggested that it may have potential neurotoxic effects, indicating the need for further investigation into its safety profile.

Dosing information:

There is no specific dosing information available for AMOPP. The dosage would depend on the type of medical condition being treated and should be determined by a qualified healthcare professional.

Conclusion:

In conclusion, AMOPP is a promising chemical compound with potential therapeutic applications in the treatment of various medical conditions such as cancer and central nervous system disorders. While its exact mechanism of action and safety profile are not fully understood, the compound's potential cytotoxic and neuroprotective effects make it an interesting candidate for further study. Future research will help to elucidate its mechanism of action, safety profile, and pharmacological properties, which will be important in determining its potential use as a therapeutic agent

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code